Clinical Trials Logo

Clinical Trial Summary

The study is designed to evaluate the clinical efficacy, safety and tolerability of selumetinib with radioactive iodine therapy in patients with differentiated thyroid cancer.


Clinical Trial Description

A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01843062
Study type Interventional
Source AstraZeneca
Contact
Status Terminated
Phase Phase 3
Start date August 27, 2013
Completion date March 6, 2019

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02870569 - Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer Phase 2
Completed NCT01876784 - Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Phase 3
Completed NCT04971473 - Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal Phase 3
Recruiting NCT04964284 - Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer Phase 3
Recruiting NCT05078853 - Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
Active, not recruiting NCT03690388 - A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy Phase 3
Recruiting NCT02638077 - Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China N/A
Recruiting NCT01700699 - Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT04563780 - The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
Completed NCT03191643 - PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer N/A
Completed NCT02278198 - Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123 Phase 1
Active, not recruiting NCT04447183 - The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. Phase 2
Active, not recruiting NCT01263951 - Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone Phase 2
Active, not recruiting NCT04940052 - Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer Phase 3
Recruiting NCT04880798 - Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer N/A
Recruiting NCT05789667 - Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
Recruiting NCT05660954 - Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Phase 2
Completed NCT00295763 - A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Phase 3